Megasoft Limited has informed the Exchange about General Updates-Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015
SIGMAADV · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.8 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Megasoft Limited's board, at a meeting on July 1, 2025, approved the sale of its entire 36.52% holding in Extrovis AG, Switzerland, an associate company. The buyer is Refex Life Sciences Private Limited, which is not a related party to Megasoft. The total consideration is US$15 million (approximately INR 128.40 Crores), payable in one or more tranches and subject to foreign exchange fluctuations. The Share Purchase Agreement is yet to be executed, and the company will seek shareholder approval through a postal ballot. Extrovis AG is an associate, so the disposal has no impact on Megasoft's standalone financials, with only the associate's proportionate loss reflected at the consolidated level.
Shareholders will see Megasoft receive roughly INR 128 Crores in cash, which could strengthen the balance sheet once the deal closes. Since the stake is in an associate with no standalone impact, the divestment is largely a portfolio reshuffle rather than a change in core operations, though completion is still subject to a definitive agreement and shareholder vote.